William Blair & Company
TXMD icon

William Blair & Company’s TherapeuticsMD TXMD Stock Holding History

William Blair & Company’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-500
Closed -$259K – 1245
2015
Q4 		$259K Buy
500
+300
+150% +$111K ﹤0.01% 997
2015
Q3 		$58K Buy
+200
New +$71.1K ﹤0.01% 1353

Other funds holding TXMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

William Blair & Company's TXMD Position: Q1 2016 in Review

William Blair & Company sold out of TherapeuticsMD (TXMD) in Q1 2016, closing a stake of 500 shares — an estimated $259K sold.

William Blair & Company first reported a position in TXMD in Q3 2015 and held it in 2 quarters. The position peaked at $259K in Q4 2015. 128 funds tracked by Wall St. Rank hold TXMD as of Q1 2016.

  • William Blair & Company reported no remaining TherapeuticsMD position as of Q1 2016 after selling out during the quarter.
  • William Blair & Company sold 500 TherapeuticsMD shares in Q1 2016, an estimated $259K.
  • William Blair & Company first reported a position in TherapeuticsMD in Q3 2015 and held it in 2 quarters.
  • William Blair & Company's TherapeuticsMD position peaked at $259K in Q4 2015.
  • 128 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2016.

Based on William Blair & Company's 13F filing for Q1 2016, filed 16 May 2016.